Disclaimer

This application is an educational and research tool that provides simulation results based on pharmacokinetic models.

The displayed results are theoretical values and do not guarantee actual clinical patient responses.

Do not use this application as the basis for actual clinical decisions.

All clinical decisions should be made by qualified medical professionals at their own responsibility.

Patient Information

Rocuronium PK/PD Simulator

Patient Details

Patient-2025-07-13
50 years
70.0 kg
170 cm
24.2
Male
Wierda
08:00

Dosing Schedule

Multiple dose changes are possible

—

No Simulation Results

Please run a simulation from the Dosing tab

Simulation Results

Peak Plasma Concentration

0.000 µg/mL

Peak Effect-Site Concentration

0.000 µg/mL
Time Plasma Concentration Effect-Site Concentration TOF Ratio

Rocuronium PK/PD Simulator

Version 1.1.0

Enhanced RK4 Integration

Important Usage Limitations

This software is intended for educational and research purposes only.

  • This software is not a medical device
  • Do not use for diagnosis, treatment, or any clinical purposes or patient care
  • The author assumes no responsibility for any results arising from the use of this software

Scientific Evidence

This application is based on the following research:

Rocuronium Pharmacodynamic Model

Masui, K., Ishigaki, S., Tomita, A. et al.

J Anesth 32, 709–716 (2018).

doi:10.1007/s00540-018-2543-3

Enhanced RK4 Integration (V1.1.0)

Numerical Precision Upgrade: This version implements unified 4-dimensional Runge-Kutta integration for superior accuracy.

4-Dimensional RK4 System

  • Simultaneous Integration: Plasma (a1, a2, a3) and effect-site (Ce) concentrations calculated together
  • Proper Differential Equation: dCe/dt = ke0 × (Cp - Ce) with 4th-order accuracy
  • Precision Improvement: ~1000x better accuracy vs Euler method
  • Numerical Stability: Enhanced stability for pharmacokinetic modeling

Benefits for Clinical Simulation

  • Higher Accuracy: Professional-grade numerical precision for research applications
  • Consistent Results: Unified approach across propofol, remimazolam, and rocuronium simulators
  • Time Resolution: 0.01-minute precision (0.6-second accuracy) maintained
  • Non-negative Constraints: Physically meaningful concentration values ensured

Developer Information

YASUYUKI SUZUKI

ORCID: 0000-0002-4871-9685

Affiliation:

  • Department of Anesthesiology, Saiseikai Matsuyama Hospital
  • Department of Pharmacology, Ehime University Graduate School of Medicine

Development: JavaScript/HTML/CSS

Developed with Claude Code (Anthropic)

Calculation Model Details

This simulator implements five pharmacokinetic (PK) models and their corresponding pharmacodynamic (PD) models validated in Masui et al. (2018). Different PK models may result in varying plasma and effect-site concentration profiles, requiring careful interpretation of results.

Wierda Model (1991)

Features: One of the earliest referenced basic 3-compartment models, used as a comparison standard in many subsequent studies.

Clinical Significance: Serves as a benchmark for understanding rocuronium kinetics in standard patients. Shows similar plasma concentration profiles to Cooper and Alvarez-Gomez models.

Szenohradszky Model (1992)

Features: 3-compartment model built from data in normal kidney function and kidney transplant patients. Tends to calculate significantly higher initial plasma concentrations compared to other models.

Clinical Significance: May overestimate plasma concentrations according to the literature. Consequently calculates higher effect-site concentrations and may predict faster TOF ratio recovery than other models.

Cooper Model (1993)

Features: 3-compartment model from research comparing the effects of kidney function. Shows relatively similar kinetics to the Wierda model.

Clinical Significance: Referenced as a general-purpose model alongside Wierda and Alvarez-Gomez, developed with kidney function impairment patients in mind.

Alvarez-Gomez Model (1994)

Features: 3-compartment model for adult patients. Shows very similar simulation results to Wierda and Cooper in this comparative study.

Clinical Significance: Widely accepted as one of the standard models, with validity verified in multiple studies.

McCoy Model (1996)

Features: The only 2-compartment model among these options. PD parameter (ke0) is not affected by age.

Clinical Significance: Simpler model structure allows easier calculation but may differ from 3-compartment models, especially in distribution phase representation. Tends to calculate higher effect-site concentrations than other models during the first 30 minutes post-administration.

Data and Privacy

This software does not collect, store, or transmit any data entered by users. All calculations are performed locally in your browser.

Edit Patient Information

Add Dose Event

Set both bolus and continuous infusion to 0 to stop dosing